Found 2 hits in this display Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Neuropeptide Y receptor type 2
(Homo sapiens (Human)) | BDBM50269168
(CHEMBL4069205)Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C84H145N31O19/c1-45(117)65(77(132)107-53(27-16-34-99-82(92)93)67(122)105-55(30-31-63(85)119)70(125)103-51(25-14-32-97-80(88)89)68(123)108-56(66(87)121)37-47-19-8-5-9-20-47)113-79(134)84(3,4)114-75(130)54(28-17-35-100-83(94)95)104-74(129)60(41-64(86)120)112-72(127)58(39-49-23-12-7-13-24-49)109-71(126)57(38-48-21-10-6-11-22-48)110-73(128)59(40-50-42-96-44-101-50)111-69(124)52(26-15-33-98-81(90)91)106-76(131)62-29-18-36-115(62)78(133)61(43-116)102-46(2)118/h42,44-45,47-49,51-62,65,116-117H,5-41,43H2,1-4H3,(H2,85,119)(H2,86,120)(H2,87,121)(H,96,101)(H,102,118)(H,103,125)(H,104,129)(H,105,122)(H,106,131)(H,107,132)(H,108,123)(H,109,126)(H,110,128)(H,111,124)(H,112,127)(H,113,134)(H,114,130)(H4,88,89,97)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,65+/m1/s1 | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| Article PubMed
| n/a | n/a | 0.600 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company, Ltd.
Curated by ChEMBL
| Assay Description Displacement of [125I]peptide YY from human Y2 receptor expressed in CHO cell membranes after 60 mins by TopCount scintillation counting analysis |
Bioorg Med Chem Lett 27: 3829-3832 (2017)
Article DOI: 10.1016/j.bmcl.2017.06.055 BindingDB Entry DOI: 10.7270/Q2MK6GC2 |
More data for this Ligand-Target Pair | |
Neuropeptide Y receptor type 2
(Homo sapiens (Human)) | BDBM50269168
(CHEMBL4069205)Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O |r| Show InChI InChI=1S/C84H145N31O19/c1-45(117)65(77(132)107-53(27-16-34-99-82(92)93)67(122)105-55(30-31-63(85)119)70(125)103-51(25-14-32-97-80(88)89)68(123)108-56(66(87)121)37-47-19-8-5-9-20-47)113-79(134)84(3,4)114-75(130)54(28-17-35-100-83(94)95)104-74(129)60(41-64(86)120)112-72(127)58(39-49-23-12-7-13-24-49)109-71(126)57(38-48-21-10-6-11-22-48)110-73(128)59(40-50-42-96-44-101-50)111-69(124)52(26-15-33-98-81(90)91)106-76(131)62-29-18-36-115(62)78(133)61(43-116)102-46(2)118/h42,44-45,47-49,51-62,65,116-117H,5-41,43H2,1-4H3,(H2,85,119)(H2,86,120)(H2,87,121)(H,96,101)(H,102,118)(H,103,125)(H,104,129)(H,105,122)(H,106,131)(H,107,132)(H,108,123)(H,109,126)(H,110,128)(H,111,124)(H,112,127)(H,113,134)(H,114,130)(H4,88,89,97)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,65+/m1/s1 | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| Article PubMed
| n/a | n/a | n/a | n/a | 0.160 | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company, Ltd.
Curated by ChEMBL
| Assay Description Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay |
Bioorg Med Chem Lett 27: 3829-3832 (2017)
Article DOI: 10.1016/j.bmcl.2017.06.055 BindingDB Entry DOI: 10.7270/Q2MK6GC2 |
More data for this Ligand-Target Pair | |